GSK plc Stock price

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe 07:31:35 2024-03-19 am EDT 5-day change 1st Jan Change
1,661 GBX +0.01% Intraday chart for GSK plc -1.35% +14.63%
Sales 2024 * 31.56B 40.03B Sales 2025 * 33.49B 42.49B Capitalization 67.4B 85.49B
Net income 2024 * 5.61B 7.11B Net income 2025 * 6.25B 7.93B EV / Sales 2024 * 2.53 x
Net Debt 2024 * 12.57B 15.95B Net Debt 2025 * 9.37B 11.88B EV / Sales 2025 * 2.29 x
P/E ratio 2024 *
12.1 x
P/E ratio 2025 *
10.7 x
Employees 70,212
Yield 2024 *
3.68%
Yield 2025 *
3.97%
Free-Float 92%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.01%
1 week-1.35%
Current month-0.13%
1 month-0.41%
3 months+16.02%
6 months+10.61%
Current year+14.63%
More quotes
1 week
1 644.80
Extreme 1644.8
1 700.00
1 month
1 644.80
Extreme 1644.8
1 719.80
Current year
1 453.20
Extreme 1453.2
1 719.80
1 year
1 302.60
Extreme 1302.6
1 719.80
3 years
1 280.92
Extreme 1280.92
3 408.16
5 years
1 280.92
Extreme 1280.92
3 408.16
10 years
1 280.92
Extreme 1280.92
3 408.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 10-04-30
Director of Finance/CFO 62 23-04-30
Compliance Officer - 95-07-31
Members of the board TitleAgeSince
Director of Finance/CFO 62 23-04-30
Chairman 66 19-08-31
Director/Board Member 65 14-12-31
More insiders
Date Price Change Volume
24-03-19 1,662 +0.10% 517 644
24-03-18 1,661 +0.68% 9,509,166
24-03-15 1,650 -2.26% 19,016,980
24-03-14 1,688 -0.44% 5,252,450
24-03-13 1,695 +0.59% 9,359,088

Delayed Quote London S.E., March 19, 2024 at 07:16 am EDT

More quotes
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. The Company owns camlipixant, a selective P2X3 antagonist, which is in Phase III development for the treatment of refractory chronic cough (RCC).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
16.61 GBP
Average target price
19.89 GBP
Spread / Average Target
+19.76%
Consensus
  1. Stock
  2. Equities
  3. Stock GSK plc - London S.E.